| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,633 |
9,514 |
$786K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
16,059 |
11,557 |
$635K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
17,475 |
11,437 |
$394K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,724 |
2,450 |
$295K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
5,481 |
3,725 |
$289K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,472 |
1,690 |
$121K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,410 |
3,674 |
$92K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,027 |
1,418 |
$47K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,461 |
3,020 |
$40K |
| 99215 |
Prolong outpt/office vis |
118 |
49 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
58 |
52 |
$3K |
| 87807 |
|
312 |
227 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
143 |
90 |
$1K |
| 87428 |
|
63 |
29 |
$890.26 |
| 81003 |
|
138 |
111 |
$251.55 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
49 |
38 |
$4.80 |
| 99072 |
|
2,480 |
1,694 |
$0.00 |
| 99000 |
|
152 |
96 |
$0.00 |
| H0033 |
Oral medication administration, direct observation |
38 |
30 |
$0.00 |
| A9150 |
Non-prescription drugs |
24 |
17 |
$0.00 |